Lindbrook Capital’s Clearside Biomedical CLSD Stock Holding History

Lindbrook Capital’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-667	Closed	-$29K	–	1705
2019 Q4	$29K	Buy	+667	New	+$14K	0.01%	611

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Lindbrook Capital's CLSD Position: Q1 2020 in Review

Lindbrook Capital sold out of Clearside Biomedical (CLSD) in Q1 2020, closing a stake of 667 shares — an estimated $29K sold.

Lindbrook Capital first reported a position in CLSD in Q4 2019 and held it in 1 quarter. The position peaked at $29K in Q4 2019. 43 funds tracked by Wall St. Rank hold CLSD as of Q1 2020.

Lindbrook Capital reported no remaining Clearside Biomedical position as of Q1 2020 after selling out during the quarter.
Lindbrook Capital sold 667 Clearside Biomedical shares in Q1 2020, an estimated $29K.
Lindbrook Capital first reported a position in Clearside Biomedical in Q4 2019 and held it in 1 quarter.
Lindbrook Capital's Clearside Biomedical position peaked at $29K in Q4 2019.
43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2020.

Based on Lindbrook Capital's 13F filing for Q1 2020, filed 22 Apr 2020.